Key updates in thalassemia at ASH 2023: gene therapies, ongoing trials & the value of precision medicine

In the last decade, the treatment landscape of thalassemia has been transformed with the introduction of novel therapies. With several agents being evaluated in clinical trials, the future looks promising for patients. Despite these advances, there are challenges and unmet needs which remain, and both clinicians and researchers are working to address these, with the goal of improving outcomes for patients. In this podcast, you will hear from experts Maria Domenica Cappellini, MD, University of Milan, Milan, Italy, and Kevin Kuo, MD, MSc, FRCPC, University Health Network, Toronto, Canada, who discuss recent updates in thalassemia presented at the 2023 ASH Annual Meeting. The experts cover several topics, including the promise of novel gene therapies, the BEYOND trial (NCT03342404), and more.